Primary central nervous system lymphoma Secondary Prevention: Difference between revisions

	Primary central nervous system lymphoma Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Primary Central Nervous System Lymphoma from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Staging
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Echocardiography and Ultrasound
CT
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Primary central nervous system lymphoma Secondary Prevention On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Primary central nervous system lymphoma Secondary Prevention All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Primary central nervous system lymphoma Secondary Prevention
CDC on Primary central nervous system lymphoma Secondary Prevention
Primary central nervous system lymphoma Secondary Prevention in the news
Blogs on Primary central nervous system lymphoma Secondary Prevention
Directions to Hospitals Treating Primary central nervous system lymphoma
Risk calculators and risk factors for Primary central nervous system lymphoma Secondary Prevention

Latest revision as of 14:16, 22 May 2019

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

There are no established measures for the secondary prevention of [disease name].

OR

Effective measures for the secondary prevention of [disease name] include [strategy 1], [strategy 2], and [strategy 3].

There are no established measures for the secondary prevention of [disease name].

OR

Effective measures for the secondary prevention of [disease name] include:

@@ Line 1: / Line 1: @@
 __NOTOC__
-{{Xyz}}
+{{Primary central nervous system lymphoma}}
 {{CMG}}; {{AE}}
 ==Overview==
-There are no established measures for the primary prevention of [disease name].
+There are no established measures for the secondary prevention of [disease name].
 OR
-There are no available vaccines against [disease name].
+Effective measures for the secondary prevention of [disease name] include [strategy 1], [strategy 2], and [strategy 3].
-OR
+==Secondary Prevention==
+There are no established measures for the secondary prevention of [disease name].
-Effective measures for the primary prevention of [disease name] include [measure1], [measure2], and [measure3].
-OR
-[Vaccine name] vaccine is recommended for [patient population] to prevent [disease name]. Other primary prevention strategies include [strategy 1], [strategy 2], and [strategy 3].
-==Primary Prevention==
-There are no established measures for the primary prevention of [disease name].
-OR
-There are no available vaccines against [disease name].
-OR
-Effective measures for the primary prevention of [disease name] include:
-*[Measure1]
-*[Measure2]
-*[Measure3]
 OR
-[Vaccine name] vaccine is recommended for [patient population] to prevent [disease name]. Other primary prevention strategies include:
+Effective measures for the secondary prevention of [disease name] include:
 *[Strategy 1]
 *[Strategy 2]
@@ Line 44: / Line 25: @@
 {{WH}}
 {{WS}}
+[[Category: (name of the system)]]